Display Settings:

Format

Send to:

Choose Destination

    Braz J Med Biol Res. 2006 Feb;39(2):277-81. Epub 2006 Feb 2.

    Effect of topical dorzolamide on rabbit central corneal thickness.

    Almeida GC Jr, Faria e Souza SJ.

    Departamento de Especialidades Cirúrgicas, Oftalmologia, Faculdade de Medicina Estadual de São José do Rio Preto, São José do Rio Preto, SP, Brazil. gcaj@uol.com.br

    Our objective was to study the effect of dorzolamide on corneal hydration in an 18-week controlled experiment using ultrasonic pachymetry. Twenty-eight male rabbits were divided randomly into four groups. The 7 rabbits in each group received eye drops containing either 2% (w/v) dorzolamide or placebo in their right eye, or in their left eye. The 2% dorzolamide rabbits were treated every 8 h. Fellow eyes are defined as eyes which did not receive either dorzolamide or placebo. The study was blind for both the person who applied the drug and the one who performed the pachymetry. The effect of treatments is reported on the basis of the percentage of pachymetric variation compared to the measurement made before drug application. There was no significant difference (P = 0.061) in pachymetric variation between dorzolamide (-4.42 +/- 11.71%) and placebo (2.48 +/- 9.63%). However, there was a significant difference (P = 0.0034) in pachymetric variation between the dorzolamide fellow eyes (-7.56 +/- 10.50%) and the placebo (-4.42 +/- 11.71%). In conclusion, dorzolamide did not increase the corneal thickness in rabbits.

    PMID: 16470316 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Dorzolamide Ophthalmic (Trusopt® Ocumeter® Plus)

      Dorzolamide is used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Dorzolamide decreases the pressure in the eye.